SCHEMBL5224201

SCHEMBL5224201

C1CN2CCN1CC2.Cc1ccc(S(=O)(=O)OCCc2ccc(Br)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
EGFR P00533 1/20 0.42
ERBB2 P04626 1/20 0.42
KDM4E B2RXH2 2/20 0.41
POLB P06746 1/20 0.41
APEX1 P27695 1/20 0.41
RECQL P46063 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CYP2D6 P10635 3/20 0.39
ALDH1A1 P00352 4/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CYP3A4 P08684 2/20 0.38
TSHR P16473 2/20 0.38
CYP2C19 P33261 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL828951 0.93 EGFR (0.47) CYP1A2CYP2C9EGFRERBB2KDM4E
SCHEMBL16898479 0.86 EGFR (0.44) CYP1A2CYP2C9EGFRERBB2KDM4E
SCHEMBL6906905 0.85 CA1 (0.50) CYP2C9CA1CA2ALDH1A1KMT2A
SCHEMBL18289524 0.85 CA1 (0.50) CYP2C9CA1CA2ALDH1A1KMT2A
SCHEMBL5351657 0.81 CA1 (0.51) EGFRERBB2CA1CA2ALDH1A1
SCHEMBL18530411 0.80 ALDH1A1 (0.45) CA1CA2ALDH1A1KMT2AMEN1
SCHEMBL4824193 0.79 FDFT1 (0.41) CYP1A2CYP2C9EGFRERBB2KDM4E
SCHEMBL948326 0.79 CNR2 (0.56) CYP2C9EGFRERBB2CA1CA2
SCHEMBL4432596 0.79 CA1 (0.49) CA1CA2ALDH1A1MAPTKMT2A
SCHEMBL21524969 0.79 CA1 (0.48) CYP1A2RECQLCA1CA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1833822-A2 COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY Theravance, Inc. (US) 2007-09-19 EP disclosed
WO-2006023460-A2 COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY THERAVANCE, INC. (US) 2006-03-02 WO disclosed